Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-25 @ 12:31 AM
Ignite Modification Date:
2025-12-25 @ 10:39 PM
NCT ID:
NCT02162667
Group ID:
EG001
Title:
Herceptin
Description:
Patient received Herceptin at an initial dose of 8 mg/kg administered by a single IV infusion on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycles 2 through 8 (3-week cycles). Patients also received docetaxel 75 mg/m\^2 during cycles 1 through 4 and FEC (fluorouracil 500mg/m\^2, epirubicin 75mg/m\^2, and cyclophosphamide 500mg/m\^2) during Cycles 5 through 8. After a total of 8 treatment cycles of the neoadjuvant treatment, surgery was performed within 3 to 6 weeks from the last dose of study. Three to 6 weeks after surgery, patients entered the adjuvant period and received additional Herceptin 6 mg/kg (3-week cycles) for up to 1 year from the first day of study drug administration in the Neoadjuvant Period, excluding surgery (or up to 10 cycles after surgery).
Deaths Number Affected:
None
Deaths Number At Risk:
None
Serious Number Affected:
36
Serious Number At Risk:
278
Other Number Affected:
264
Other Number At Risk:
278
Study:
NCT02162667
Results Section:
NCT02162667
Adverse Events Module:
NCT02162667